Cancer nanomedicines: So many papers and so few drugs!

Advanced Drug Delivery Reviews

Volumn 65, Issue 1, 2013, Pages 80-88

  Venditto, Vincent J ^a   Szoka, Francis C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Camptothecin; Liposomes; Monoclonal antibodies; Platinum therapy; Polymers

Indexed keywords

ANTICANCER DRUG; BASIC SCIENCE; BUSINESS MODELS; CAMPTOTHECIN (CPT); CAMPTOTHECIN DERIVATIVES; CAMPTOTHECINS; CANCER THERAPEUTICS; CLINICAL TRIAL; DRUG CANDIDATES; DRUG CARRIER; LIPOSOMAL FORMULATION; MOLECULAR ENTITIES; NANOCARRIERS; NANOMEDICINES; PARENT MOLECULES; PHARMACEUTICAL COMPANY;

BODY FLUIDS; DISEASES; DRUG DELIVERY; EXPERIMENTS; LIPOSOMES; MONOCLONAL ANTIBODIES; PLATINUM; POLYMERS; PUBLISHING; SURFACE PLASMON RESONANCE;

MEDICAL NANOTECHNOLOGY;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CRLX 101; DOXORUBICIN; FIRTECAN PEGOL; GEMTUZUMAB OZOGAMICIN; IRINOTECAN; NANOCARRIER; RITUXIMAB; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CANCER RESEARCH; CANCER THERAPY; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NANOMEDICINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84873275186     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.038     Document Type: Review

References (66)

1. Feynman R.P. There's plenty of room at the bottom. Eng. Sci. (CalTech) 1960, 23:22-36.
2. Sarker D., Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 2007, 96:213-268.
3. Blanco E., Hsiao A., Mann A.P., Landry M.G., Meric-Bernstam F., Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 2011, 102:1247-1252.
4. Alexis F., Pridgen E.M., Langer R., Farokhzad O.C. Nanoparticle technologies for cancer therapy. Drug Delivery, Handbook of Experimental Pharmacology 2010, 197:55-86. Springer-Verlag, Berlin. M. Schafer-Korting (Ed.).
5. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharmaceutics 2011, 8:2101-2141.
6. F.D. Ledley, L.M. McNamee, Patterns of technological innovation in biotechnology, Nature Biotechnol. in press.
7. Venditto V.J., Simanek E.E. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol. Pharmaceutics 2010, 7:307-349.
8. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 1986, 72:6387-6392.
9. Brem H., Lawson H.C. The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents form biodegradable polymers. Cancer 1999, 86:197-199.
10. Morpurgo M., Pasut G., Veronese F.M. PEGylated proteins as cancer therapeutics. Delivery of Protein and Peptide Drugs in Cancer 2006, 85-110. World Scientific Publishing Co., Singapore. V.P. Torchilin (Ed.).
11. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 2001, 46:169-185.
12. Fox M.E., Szoka F.C., Fréchet J.M. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc. Chem. Res. 2009, 42:1141-1151.
13. Barenholz Y. Doxil - the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
14. Marcato P.D., Duran N. New aspects of nanopharmaceutical delivery systems. J. Nanosci. Nanotechnol. 2008, 8:1-14.
15. Weiner L.M., Murray J.C., Shuptrine C.W. Antibody-based immunotherapy of cancer. Cell 2012, 148:1081-1084.
16. Goodman L.S., Wintrobe M.M. Nitrogen mustard therapy. J. Am. Med. Assoc. 1946, 132:126-132.
17. Stashenko P., Nadler L.M., Hardy R., Schlosssman S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 1980, 125:1678-1685.
18. Nadler L.M., Ritz J., Hardy R., Pesando J.M., Schlossman S.F., Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 1981, 67:134-140.
19. Morrison S.L., Johnson M.J., Herzenberg S.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6851-6855.
20. Boulianne G.L., Hozumi N., Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 1984, 312:643-646.
21. Horibe K., Nadler L.M. Human B cell associated antigens defined by monoclonal antibodies. Lymphocyte Surface Antigens 1984, 309-323. American Society for Histocompatability and Immunogenetics, New York. E.L. Heise (Ed.).
22. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
23. D.R. Anderson, N. Hanna, J.E. Leonard, R.A. Newman, M.E. Reff, W.H. Rastetter, Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma, in, United States Patent 5,736,137 (1998).
24. Arcamore F., Franceschi G., Orezzi P., Cassinelli G., Barbieri W., Mondelli R. Daunomycin. I. The structure of daunomycinone. J. Am. Chem. Soc. 1964, 86:15-19.
25. Arcamore F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., Spalla C. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 1969, 11:1101-1110.
26. Bangham A.D., Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 1964, 8:660-668.
27. Gregoriadis G., Leathwood P.D., Ryman B.E. Enzyme entrapment in liposomes. FEBS Lett. 1971, 14:95-99.
28. Gregoriadis G. The carrier potential of liposomes in biology and medicine. New Engl. J. Med. 1976, 295:704-710.
29. Gregoriadis G. The carrier potential of liposomes in biology and medicine. New Engl. J. Med. 1976, 295:765-770.
30. Forssen E.A., Tokes Z.A. In vitro and in vivo studies with adriamycin liposomes. Biochim. Biophys. Res. Commun. 1979, 91:1295-1301.
31. Szoka F., Olson F., Heath T., Vail W., Mayhew E., Papahadjopoulos D. Preparation of unilamellar liposomes of intermediate size (0.1-0.2mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim. Biophys. Acta 1980, 3:559-571.
32. M.C. Woodle, M.C., F.J. Martin, A. Yau-Yang, C.T. Redmann, Liposomes with enhanced circulation time, in, United States Patent 5,013,556 (1991).
33. Y. Barenholz, Loading and controlled release of amphiphatic molecules to and from liposomes, in, United States Patent 5,192,549 (1993).
34. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphatic weak base. Biochim. Biophys. Acta 1993, 1151:201-215.
35. Lee M.D., Manning J.K., Williams D.R., Kuck N.A., Testa R.T., Borders D.B. Calicheamicins, a novel family of antitumor antibiotics. III. Isolation, purification and characterization of calicheamicins beta 1 Br, gamma 1 Br, alpha 2I, alpha 3I, beta 1I and delta 1I. J. Antibiot. 1989, 42:1070-1087.
36. Hinman L.M., Hamann P.R., Wallace R., Menendez A.T., Durr F.E., Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993, 53:3336-3342.
37. Trouet A., Masquelier M., Baurain R., Deprez-De Campeneere D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:626-629.
38. Griffin J.D., Linch D., Sabbath K., Larcom P., Schlossman S.F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. 1984, 8:521-534.
39. P.R. Hamann, L. Hinman, I. Hollander, R. Holycomb, W. Hallett, H.-R. Tsou, M.J. Weiss, Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents, in United States Patent 5,739,116 (1998).
40. Sievers E.L., Appelbaum F.R., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., Shannon-Dorcy K., Berger M.S., Bernstein I.D. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immuoconjugate. Blood 1999, 93:3678-3684.
41. Klotz I.M. The effects of salts and proteins on the spectra of some dyes and indicators. Chem. Rev. 1947, 41:373-399.
42. Collipp P.J., Snyder R.D. Short asthmatic children and human growth hormone: evaluation of albumin-bound growth hormone. Clin. Pediatr. 1968, 7:659-664.
43. Magnenat G., Schindler R., Isliker H. Transport of cytostatic agents by the plasma proteins. III. In vitro antitumor action of cytostatic-azoprotein conjugates. Eur. J. Cancer 1969, 5:33-40.
44. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties in vitro and in vivo of paclitaxel-albumin conjugate. J. Control. Res. 1997, 47:293-304.
45. N.P. Desai, N.P., C. Tao, A. Yang, L. Louie, T. Zheng, Z. Yao, P. Soon-Shiong, S. Magdassi, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof, in, United States Patent 5,916,596, (1999).
46. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8:1038-1044.
47. Miller R.A., Hart S., Samoszuk M., Coulter C., Brown S., Czerwinski D., Kelkenberg J., Roystin I., Levy R. Shared idiotypes expressed by human B-cell lymphomas. New Engl. J. Med. 1989, 321:851-857.
48. Wall M.E., Wani M.C., Cooke C.E., Palmer K.H., McPhail A.T., Sim G.A. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88:3888-3890.
49. Daud A., Valkov N., Centeno B., Derderian J., Sullivan P., Munster P., Urbas P., DeConti R.C., Berghorn E., Liu Z., Hausheer F.H., Sullivan D. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin. Cancer Res. 2005, 11:3009-3016.
50. Yurkovetskiy A.V., Fram R.J. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Delivery Rev. 2009, 61:1193-1202.
51. M.E. Davis, H. Gonzalez, S. Hwang, Linear cyclodextrin copolymers, in, United States Patent 6,509,323 (2003).
52. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 1999, 10:1068-1074.
53. Cheng J., Khin K.T., Jensen G.S., Liu A., Davis M.E. Synthesis of linear beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconj. Chem. 2003, 14:1007-1017.
54. Cheng J., Khin K.T., Davis M.E. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol. Pharmaceutics 2004, 1:183-193.
55. Davis M.E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 2009, 61:1189-1192.
56. Greenwald R.B., Pendri A., Conover C.D., Lee C., Choe Y.H., Gilbert C., Martinez A., Xia J., Wu D., Hsue M. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 1998, 6:551-562.
57. Sapra P., Kraft P., Mehlig M., Maltby J., Zhao H., Greenberger L.M., Horak I.D. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma. Haematologica 2009, 94:1456-1459.
58. D. Kirpotin, Compound-loaded liposomes and methods for their preparation, in, United States Patent, 6,110,491 (2000).
59. Sadzuka Y., Hirotsu S., Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett. 1998, 127:99-106.
60. Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., Kirpotin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006, 66:3271-3277.
61. Eisenhart M. The paradox of peer review: admitting too much or allowing too little?. Res. Sci. Educ. 2002, 32:241-255.
62. Thurner S., Hanel R. Peer-review in a world with rational scientists: toward selection of the average. Eur. Phys. J. 2011, 84:707-711.
63. National Science and Technology Council, Committee on Technology. The Nanotechnology Initiative - Supplement to the President's 2012 Budget 2011.
64. Nanotechnology Regulatory Science Act of 2011, S. 1662, 112th Cong. (2011).
65. Ratner M. Pfizer reaches out to academia - again. Nat. Biotechnol. 2011, 29:3-4.
66. National Institutes of Health NIH launches collaborative program with industry and researchers to spur therapeutic development May 3, 2012, NIH News.